218 related articles for article (PubMed ID: 30135687)
1. APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz.
Covino DA; Purificato C; Catapano L; Galluzzo CM; Gauzzi MC; Vella S; Lefebvre E; Seyedkazemi S; Andreotti M; Fantuzzi L
Front Immunol; 2018; 9():1839. PubMed ID: 30135687
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load.
Reddy K; Winkler CA; Werner L; Mlisana K; Abdool Karim SS; Ndung'u T;
AIDS; 2010 Jan; 24(2):195-204. PubMed ID: 19996938
[TBL] [Abstract][Full Text] [Related]
3. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
[TBL] [Abstract][Full Text] [Related]
4. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells.
Chen K; Huang J; Zhang C; Huang S; Nunnari G; Wang FX; Tong X; Gao L; Nikisher K; Zhang H
J Virol; 2006 Aug; 80(15):7645-57. PubMed ID: 16840343
[TBL] [Abstract][Full Text] [Related]
5. Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants.
Noguera-Julian M; Cozzi-Lepri A; Di Giallonardo F; Schuurman R; Däumer M; Aitken S; Ceccherini-Silberstein F; D'Arminio Monforte A; Geretti AM; Booth CL; Kaiser R; Michalik C; Jansen K; Masquelier B; Bellecave P; Kouyos RD; Castro E; Furrer H; Schultze A; Günthard HF; Brun-Vezinet F; Metzner KJ; Paredes R;
Clin Microbiol Infect; 2016 Feb; 22(2):191-200. PubMed ID: 26482266
[TBL] [Abstract][Full Text] [Related]
6. APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count.
Cho SJ; Drechsler H; Burke RC; Arens MQ; Powderly W; Davidson NO
J Virol; 2006 Feb; 80(4):2069-72. PubMed ID: 16439564
[TBL] [Abstract][Full Text] [Related]
7. Reversible Human Immunodeficiency Virus Type-1 Latency in Primary Human Monocyte-Derived Macrophages Induced by Sustained M1 Polarization.
Graziano F; Aimola G; Forlani G; Turrini F; Accolla RS; Vicenzi E; Poli G
Sci Rep; 2018 Sep; 8(1):14249. PubMed ID: 30250078
[TBL] [Abstract][Full Text] [Related]
8. APOBEC3G levels predict rates of progression to AIDS.
Jin X; Wu H; Smith H
Retrovirology; 2007 Mar; 4():20. PubMed ID: 17374143
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals.
Biasin M; Piacentini L; Lo Caputo S; Kanari Y; Magri G; Trabattoni D; Naddeo V; Lopalco L; Clivio A; Cesana E; Fasano F; Bergamaschi C; Mazzotta F; Miyazawa M; Clerici M
J Infect Dis; 2007 Apr; 195(7):960-4. PubMed ID: 17330785
[TBL] [Abstract][Full Text] [Related]
10. An Alu Element Insertion in Intron 1 Results in Aberrant Alternative Splicing of APOBEC3G Pre-mRNA in Northern Pig-Tailed Macaques (
Zhang XL; Luo MT; Song JH; Pang W; Zheng YT
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776266
[TBL] [Abstract][Full Text] [Related]
11. CUL5 and APOBEC3G Polymorphisms are Partially Implicated in HIV-1 Infection and Antiretroviral Therapy in a Brazilian Population.
da Silva RC; Coelho AVC; de Moura RR; Arraes LC; Brandão LAC; Guimarães RL; Crovella S
Curr HIV Res; 2017; 15(4):245-257. PubMed ID: 28302043
[TBL] [Abstract][Full Text] [Related]
12. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus.
Thompson M; Saag M; DeJesus E; Gathe J; Lalezari J; Landay AL; Cade J; Enejosa J; Lefebvre E; Feinberg J
AIDS; 2016 Mar; 30(6):869-78. PubMed ID: 26636929
[TBL] [Abstract][Full Text] [Related]
13. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
14. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
Franca R; Spadari S; Maga G
Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
Stopak K; de Noronha C; Yonemoto W; Greene WC
Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
[TBL] [Abstract][Full Text] [Related]
16. ISG15 expression correlates with HIV-1 viral load and with factors regulating T cell response.
Scagnolari C; Monteleone K; Selvaggi C; Pierangeli A; D'Ettorre G; Mezzaroma I; Turriziani O; Gentile M; Vullo V; Antonelli G
Immunobiology; 2016 Feb; 221(2):282-90. PubMed ID: 26563749
[TBL] [Abstract][Full Text] [Related]
17. [Cellular restriction factors that inhibit human immunodeficiency virus replication: new strategies in antiretroviral therapy].
Moreno-Valencia Y; Alvarez-García LX; Vázquez-Pérez JA
Rev Invest Clin; 2014; 66(4):359-68. PubMed ID: 25695302
[TBL] [Abstract][Full Text] [Related]
18. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
Wang J; Shaban NM; Land AM; Brown WL; Harris RS
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
[TBL] [Abstract][Full Text] [Related]
19. [APOBEC3 hypermutations in HIV-1 infected cases in Turkey].
Sayan M; Simşek F; Ceran N; Dokuzoğuz B; Eraksoy H
Mikrobiyol Bul; 2013 Jul; 47(3):482-92. PubMed ID: 23971925
[TBL] [Abstract][Full Text] [Related]
20. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia.
Jin X; Brooks A; Chen H; Bennett R; Reichman R; Smith H
J Virol; 2005 Sep; 79(17):11513-6. PubMed ID: 16103203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
